Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.75)
# 623
Out of 4,408 analysts
398
Total ratings
49.6%
Success rate
15.5%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintained: Buy | $50 → $40 | $11.61 | +244.53% | 10 | Jun 1, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $42 | $7.07 | +494.06% | 25 | May 27, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Initiated Coverage: Buy | $34.95 | $8.72 | +300.80% | 1 | May 21, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $50 → $56 | $38.98 | +43.66% | 10 | May 12, 2026 | |
| TRVI Trevi Therapeutics | Rated: Buy | $18 → $30 | $14.66 | +104.64% | 24 | May 8, 2026 | |
| MLYS Mineralys Therapeutics | Maintained: Buy | $52 | $23.92 | +117.39% | 13 | May 7, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $230 | $230.59 | -0.26% | 41 | May 6, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Hold | $55 | $43.86 | +25.40% | 31 | May 6, 2026 | |
| EOLS Evolus | Maintained: Buy | $17 | $6.75 | +151.85% | 26 | May 5, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | $95 | $29.63 | +220.62% | 23 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $230 → $255 | $253.25 | +0.69% | 7 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $15 | $3.76 | +298.94% | 17 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 | $43.07 | +108.96% | 8 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180 → $250 | $116.51 | +114.57% | 8 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 | $10.71 | +161.44% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.64 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.28515 | - | 18 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $0.7681 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2,181.00 | n/a | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.67 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $6.87 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.97 → $19.57 | $6.98 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $0.00752 | n/a | 6 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $4.08 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $2.28 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $10.70 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $0.6419 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $83.12 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $7.33 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $38.18 | n/a | 1 | Oct 18, 2011 |
Oculis Holding AG
Jun 1, 2026
Maintained: Buy
Price Target: $50 → $40
Current: $11.61
Upside: +244.53%
REGENXBIO
May 27, 2026
Reiterated: Buy
Price Target: $42
Current: $7.07
Upside: +494.06%
Eupraxia Pharmaceuticals Inc.
May 21, 2026
Initiated Coverage: Buy
Price Target: $34.95
Current: $8.72
Upside: +300.80%
MBX Biosciences
May 12, 2026
Reiterated: Buy
Price Target: $50 → $56
Current: $38.98
Upside: +43.66%
Trevi Therapeutics
May 8, 2026
Rated: Buy
Price Target: $18 → $30
Current: $14.66
Upside: +104.64%
Mineralys Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $52
Current: $23.92
Upside: +117.39%
Jazz Pharmaceuticals
May 6, 2026
Reiterated: Buy
Price Target: $230
Current: $230.59
Upside: -0.26%
Supernus Pharmaceuticals
May 6, 2026
Maintained: Hold
Price Target: $55
Current: $43.86
Upside: +25.40%
Evolus
May 5, 2026
Maintained: Buy
Price Target: $17
Current: $6.75
Upside: +151.85%
Viking Therapeutics
Apr 30, 2026
Maintained: Buy
Price Target: $95
Current: $29.63
Upside: +220.62%
Apr 27, 2026
Reiterated: Buy
Price Target: $230 → $255
Current: $253.25
Upside: +0.69%
Mar 31, 2026
Maintained: Buy
Price Target: $17 → $15
Current: $3.76
Upside: +298.94%
Feb 27, 2026
Maintained: Buy
Price Target: $90
Current: $43.07
Upside: +108.96%
Feb 24, 2026
Reiterated: Buy
Price Target: $180 → $250
Current: $116.51
Upside: +114.57%
Jan 15, 2026
Maintained: Buy
Price Target: $28
Current: $10.71
Upside: +161.44%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.64
Upside: -
Dec 16, 2025
Rated: Hold
Price Target: n/a
Current: $0.28515
Upside: -
Apr 1, 2025
Maintained: Buy
Price Target: $8
Current: $0.7681
Upside: n/a
Jan 8, 2025
Maintained: Buy
Price Target: n/a
Current: $2,181.00
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $2.67
Upside: n/a
Aug 30, 2023
Maintained: Hold
Price Target: $11
Current: $6.87
Upside: n/a
Nov 3, 2022
Maintained: Buy
Price Target: $20.97 → $19.57
Current: $6.98
Upside: n/a
Oct 19, 2022
Downgraded: Hold
Price Target: $63
Current: $0.00752
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $4.08
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $5
Current: $2.28
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $10.70
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $0.6419
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $83.12
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $7.33
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $38.18
Upside: n/a